Joint Commission International launches hand hygiene tool, helps hospitals reduce infections

Food and Healthcare Press Releases Friday April 4, 2014 10:31
OAK BROOK, Illinois--4 Apr--PRNewswire/InfoQuest

Joint Commission International (JCI) is providing the Targeted Solutions Tool(R) (TST(R)) for Hand Hygiene at no additional charge to JCI-accredited health care organizations to help improve patient care and reduce health care-associated infections. Hundreds of millions of people worldwide are affected by these infections every year, leading to patient mortality and financial losses for health care providers, according to the World Health Organization.

Logo - http://photos.prnewswire.com/prnh/20130429/DC02732LOGO

The online tool was developed by the Joint Commission Center for Transforming Healthcare, a nonprofit affiliate of The Joint Commission, and has been tested by JCI-accredited health care organizations in Asia-Pacific, the Middle East, and Europe. Pilot results showed a 72% improvement in hand hygiene practices and clinicians found the TST to be effective and easy to use.

"The TST is an innovative way to improve care and reduce devastating and costly health care-associated infections," explains Erin DuPree, MD, chief medical officer and vice president, Joint Commission Center for Transforming Healthcare.

The TST guides health care organizations through an effective quality improvement project, providing a step-by-step process to collect baseline data, identify problem areas, implement solutions tailored to their staff needs, and track hand hygiene improvements. Users have access to real-time data analysis, training materials, and methods to chart progress.

"JCI partners with its accredited organizations on their performance improvement journey. This tool is another valuable resource offered to JCI-accredited hospitals and clinics to help them maintain the highest level of quality and patient safety," says Paul Chang, MD, vice president, Accreditation, Standards, and Measurement, JCI.

About Joint Commission International

Joint Commission International(R) (JCI) was established in 1994 as a division of Joint Commission Resources, Inc.(R) (JCR), a wholly controlled, not-for-profit affiliate of The Joint Commission. Through international accreditation, advisory services, publications, and education programs, JCI extends The Joint Commission's mission worldwide by helping to improve the quality of patient care. JCI assists international health care organizations, public health agencies, health ministries, and others in more than 100 countries. Visit www.jointcommissioninternational.org for more information.

About the Joint Commission Center for Transforming Healthcare

Established in 2008, the Joint Commission Center for Transforming Healthcare aims to solve health care's most critical safety and quality problems. The Center's participants use a systematic approach to analyze specific breakdowns in care and discover their underlying causes to develop targeted solutions that solve these complex problems. Learn more at centerfortransforminghealthcare.org.


Latest Press Release

Medical Device Manufacturer Advant Medical Celebrates Its 25th Anniversary

Advant is a successful medical device manufacturer with corporate offices located in Galway, Ireland. For a quarter of a century, Advant has seen significant growth and development expanding into two locations in Ireland, Mexico and Costa Rica. With over...

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Related Topics